CORT
$114.03-1.05%
as of close, Oct 1, 2026
☾ AH $114.03 -1.05%
Corcept Therapeutics IncorporatedStock · Health CareNasdaq Composite 0.02%Russell 1000 0.01%Russell 3000 0.01%US Stock Market 0.01%
CORT SEC filings (2026)
CIK 1088856 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in December
2,038 filings on EDGAR since 2001 · 24 annual, 69 quarterly, 243 current · financial statements · earnings
Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Jul 29, 2026
quarter to Jun 30, 2026
Latest 8-K
Sep 23, 2026
Directors or officers; compensation; Regulation FD disclosure
Last earnings release
Jul 29, 2026
$0.36 vs −$0.04 · ▲ 27.3%
Filings on file
2,038
since 2001, 1,331 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 238-K8-K · Directors or officers; compensation; Regulation FD disclosure
- Sep 16Insider saleVieira Roberto Wandenkolk (President, Oncology) sold 296 shares for $30K at $100.82 under a 10b5-1 plan
- Sep 15Insider saleWILSON JAMES N (Director) sold 10,000 shares for $1.1M at $110.27–$111.70 under a 10b5-1 plan
- Sep 14Insider saleLyon Joseph Douglas (See Remarks) sold 10,000 shares for $1.1M at $113.32–$114.12 under a 10b5-1 plan
- Sep 2Insider saleVieira Roberto Wandenkolk (President, Oncology) sold 58,333 shares for $6.5M at $109.35–$115.44 under a 10b5-1 plan
- Sep 1Insider saleMaduck Sean (See Remarks) sold 25,000 shares for $2.9M at $113.94–$115.61 under a 10b5-1 plan
August 2026
- Aug 26Insider salePark Kimberly (Director) sold 26,685 shares for $3.3M at $122.55
- Aug 25Insider saleMaduck Sean (See Remarks) sold 30,955 shares for $3.9M at $125.47–$126.06 under a 10b5-1 plan
- Aug 18Insider saleMAHONEY DAVID L (Director) sold 103,606 shares for $12.3M at $117.47–$119.64 under a 10b5-1 plan
- Aug 17Insider saleRobb Gary Charles (Chief Business Officer) sold 10,000 shares for $1.2M at $116.26
- Aug 14Insider saleWILSON JAMES N (Director) sold 10,000 shares for $1.1M at $110.49–$112.64 under a 10b5-1 plan
- Aug 14Insider saleMaduck Sean (See Remarks) sold 3,664 shares for $419K at $114.49 under a 10b5-1 plan
- Aug 10Insider saleGuyer William (Chief Development Officer) sold 16,300 shares for $1.8M at $113.18–$114.04 under a 10b5-1 plan
- Aug 10Insider saleMaduck Sean (See Remarks) sold 1,031 shares for $118K at $114.52 under a 10b5-1 plan
- Aug 4Insider saleGuyer William (Chief Development Officer) sold 3,700 shares for $419K at $113.12 under a 10b5-1 plan
- Aug 3Insider saleMaduck Sean (See Remarks) sold 20,305 shares for $2.3M at $114.70 under a 10b5-1 plan
- Aug 3Insider saleLyon Joseph Douglas (See Remarks) sold 1,540 shares for $176K at $114.16
July 2026
- Jul 30Insider saleMokari Atabak (Chief Financial Officer) sold 80,000 shares for $9.2M at $105.54–$120.67 under a 10b5-1 plan
- Jul 29EarningsEarnings release — EPS $0.36 vs −$0.04 est. (+1000.0%); revenue $256.1M (+32% y/y) 27.3%
- Jul 29ReportQuarterly report, Q2 2026 — revenue $256.1M (+32% y/y), net income $43.0M, EPS $0.36
- Jul 15Insider saleMokari Atabak (Chief Financial Officer) sold 40,000 shares for $3.5M at $86.78–$89.43 under a 10b5-1 plan
- Jul 15Insider saleWILSON JAMES N (Director) sold 10,000 shares for $883K at $86.78–$89.49 under a 10b5-1 plan
- Jul 7Insider saleGuyer William (Chief Development Officer) sold 20,000 shares for $1.9M at $93.11–$93.54 under a 10b5-1 plan
- Jul 1Insider saleMaduck Sean (See Remarks) sold 25,000 shares for $2.2M at $87.33–$89.31 under a 10b5-1 plan
June 2026
- Jun 17Insider saleMAHONEY DAVID L (Director) sold 20,000 shares for $1.7M at $84.53
- Jun 178-K8-K · Other events
- Jun 16Insider saleWILSON JAMES N (Director) sold 10,000 shares for $832K at $82.69–$83.57 under a 10b5-1 plan
- Jun 15Insider saleMokari Atabak (Chief Financial Officer) sold 40,000 shares for $3.2M at $80.02–$82.45 under a 10b5-1 plan
- Jun 38-K8-K · Other events
- Jun 2Insider saleGuyer William (Chief Development Officer) sold 20,000 shares for $1.4M at $70.60 under a 10b5-1 plan
- Jun 1Insider saleMokari Atabak (Chief Financial Officer) sold 40,000 shares for $2.8M at $70.00 under a 10b5-1 plan
- Jun 1Insider saleMaduck Sean (See Remarks) sold 25,000 shares for $1.8M at $70.11–$70.75 under a 10b5-1 plan
- Jun 1Insider saleBELANOFF JOSEPH K (Chief Executive Officer · Director) sold 12,837 shares for $895K at $69.74 under a 10b5-1 plan
May 2026
- May 288-K8-K · Directors or officers; compensation; Shareholder vote results
- May 27Insider saleMaduck Sean (See Remarks) sold 75,000 shares for $4.9M at $65.37–$66.16 under a 10b5-1 plan
- May 27Insider saleLyon Joseph Douglas (See Remarks) sold 5,000 shares for $325K at $65.00
- May 5Insider saleGuyer William (Chief Development Officer) sold 20,000 shares for $1.0M at $51.83 under a 10b5-1 plan
- May 1Insider saleBELANOFF JOSEPH K (Chief Executive Officer · Director) sold 40,000 shares for $2.0M at $50.10 under a 10b5-1 plan
April 2026
- Apr 30EarningsEarnings release — EPS −$0.30 vs −$0.30 est. (+0.0%); revenue $164.9M (+5% y/y) 10.5%
- Apr 30ReportQuarterly report, Q1 2026 — revenue $164.9M (+5% y/y), net income −$31.8M, EPS −$0.30
- Apr 17ProxyProxy · Proxy statement
- Apr 7Insider saleGuyer William (Chief Development Officer) sold 20,000 shares for $819K at $40.97 under a 10b5-1 plan
March 2026
- Mar 25Insider saleBELANOFF JOSEPH K (Chief Executive Officer · Director) sold 26,198 shares for $1.3M at $50.07 under a 10b5-1 plan
- Mar 258-K8-K · Other events
- Mar 20Insider saleGuyer William (Chief Development Officer) sold 11,767 shares for $424K at $36.01 under a 10b5-1 plan
- Mar 17Insider buyBAKER G LEONARD JR (Director) bought 100,000 shares for $3.3M at $33.00–$33.56
- Mar 4Insider saleGuyer William (Chief Development Officer) sold 8,233 shares for $296K at $35.99 under a 10b5-1 plan
February 2026
- Feb 24EarningsEarnings release — EPS $0.20 vs $0.27 est. (−25.9%); revenue $202.1M (+11% y/y) 0.7%
- Feb 24ReportAnnual report, FY2025 — revenue $761.4M (+13% y/y), net income $99.7M, EPS $0.82
- Feb 198-K8-K · Other events
- Feb 3Insider saleGuyer William (Chief Development Officer) sold 20,000 shares for $817K at $40.87 under a 10b5-1 plan
January 2026
- Jan 228-K8-K · Other events
- Jan 6Insider saleGuyer William (Chief Development Officer) sold 20,000 shares for $704K at $35.18 under a 10b5-1 plan
December 2025
- Dec 318-K8-K · Other events
November 2025
October 2025
- Oct 148-K8-K · Termination of a material agreement
- Oct 68-K8-K · Directors or officers; compensation
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $81.5M in 38 sales and bought $3.3M in 1 purchase; 125 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 16, 2026Form 4 | Vieira Roberto WandenkolkPresident, OncologySold · $30K · 296 sh · 10b5-1 |
| Sep 15, 2026Form 4 | WILSON JAMES NDirectorSold · $1.1M · 10,000 sh · 10b5-1 |
| Sep 14, 2026Form 4 | Lyon Joseph DouglasSee RemarksSold · $1.1M · 10,000 sh · 10b5-1 |
| Sep 2, 2026Form 4 | Vieira Roberto WandenkolkPresident, OncologySold · $6.5M · 58,333 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Maduck SeanSee RemarksSold · $2.9M · 25,000 sh · 10b5-1 |
| Aug 26, 2026Form 4 | Park KimberlyDirectorSold · $3.3M · 26,685 sh |
| Aug 25, 2026Form 4 | Maduck SeanSee RemarksSold · $3.9M · 30,955 sh · 10b5-1 |
| Aug 18, 2026Form 4 | MAHONEY DAVID LDirectorSold · $12.3M · 103,606 sh · 10b5-1 |
| Aug 17, 2026Form 4 | Robb Gary CharlesChief Business OfficerSold · $1.2M · 10,000 sh |
| Aug 14, 2026Form 4 | WILSON JAMES NDirectorSold · $1.1M · 10,000 sh · 10b5-1 |
| Aug 14, 2026Form 4 | Maduck SeanSee RemarksSold · $419K · 3,664 sh · 10b5-1 |
| Aug 10, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $1.8M · 16,300 sh · 10b5-1 |
| Aug 10, 2026Form 4 | Maduck SeanSee RemarksSold · $118K · 1,031 sh · 10b5-1 |
| Aug 4, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $419K · 3,700 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Maduck SeanSee RemarksSold · $2.3M · 20,305 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Lyon Joseph DouglasSee RemarksSold · $176K · 1,540 sh |
| Jul 30, 2026Form 4 | Mokari AtabakChief Financial OfficerSold · $9.2M · 80,000 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Mokari AtabakChief Financial OfficerSold · $3.5M · 40,000 sh · 10b5-1 |
| Jul 15, 2026Form 4 | WILSON JAMES NDirectorSold · $883K · 10,000 sh · 10b5-1 |
| Jul 7, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $1.9M · 20,000 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Maduck SeanSee RemarksSold · $2.2M · 25,000 sh · 10b5-1 |
| Jun 17, 2026Form 4 | MAHONEY DAVID LDirectorSold · $1.7M · 20,000 sh |
| Jun 16, 2026Form 4 | WILSON JAMES NDirectorSold · $832K · 10,000 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Mokari AtabakChief Financial OfficerSold · $3.2M · 40,000 sh · 10b5-1 |
| Jun 2, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $1.4M · 20,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Mokari AtabakChief Financial OfficerSold · $2.8M · 40,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Maduck SeanSee RemarksSold · $1.8M · 25,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | BELANOFF JOSEPH KChief Executive Officer · DirectorSold · $895K · 12,837 sh · 10b5-1 |
| May 27, 2026Form 4 | Maduck SeanSee RemarksSold · $4.9M · 75,000 sh · 10b5-1 |
| May 27, 2026Form 4 | Lyon Joseph DouglasSee RemarksSold · $325K · 5,000 sh |
| May 5, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $1.0M · 20,000 sh · 10b5-1 |
| May 1, 2026Form 4 | BELANOFF JOSEPH KChief Executive Officer · DirectorSold · $2.0M · 40,000 sh · 10b5-1 |
| Apr 7, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $819K · 20,000 sh · 10b5-1 |
| Mar 25, 2026Form 4 | BELANOFF JOSEPH KChief Executive Officer · DirectorSold · $1.3M · 26,198 sh · 10b5-1 |
| Mar 20, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $424K · 11,767 sh · 10b5-1 |
| Mar 17, 2026Form 4 | BAKER G LEONARD JRDirectorBought · $3.3M · 100,000 sh |
| Mar 4, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $296K · 8,233 sh · 10b5-1 |
| Feb 3, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $817K · 20,000 sh · 10b5-1 |
| Jan 6, 2026Form 4 | Guyer WilliamChief Development OfficerSold · $704K · 20,000 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 125 transactions
| Date | Insider |
|---|---|
| Sep 24, 2026Form 4 | Robb Gary CharlesChief Business OfficerGift · $0 · 27,100 sh |
| Sep 17, 2026Form 4 | Robb Gary CharlesChief Business OfficerExercise or conversion · $145K · 17,493 sh |
| Sep 17, 2026Form 4 | Robb Gary CharlesChief Business OfficerExercise or conversion · Stock option (right to buy) · $0 · 17,493 sh |
| Sep 14, 2026Form 4 | Lyon Joseph DouglasSee RemarksExercise or conversion · $130K · 10,000 sh · 10b5-1 |
| Sep 14, 2026Form 4 | Lyon Joseph DouglasSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 10,000 sh · 10b5-1 |
| Sep 2, 2026Form 4 | Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · $1.3M · 58,333 sh · 10b5-1 |
| Sep 2, 2026Form 4 | Maduck SeanSee RemarksTax withholding · $13K · 117 sh · 10b5-1 |
| Sep 2, 2026Form 4 | Vieira Roberto WandenkolkPresident, OncologyTax withholding · $12K · 102 sh · 10b5-1 |
| Sep 2, 2026Form 4 | Mokari AtabakChief Financial OfficerTax withholding · $12K · 102 sh |
| Sep 2, 2026Form 4 | Robb Gary CharlesChief Business OfficerTax withholding · $10K · 91 sh |
| Sep 2, 2026Form 4 | Lyon Joseph DouglasSee RemarksTax withholding · $8,163 · 72 sh |
| Sep 2, 2026Form 4 | Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · Stock option (right to buy) · $0 · 58,333 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $207K · 25,000 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Robb Gary CharlesChief Business OfficerAward · $19K · 328 sh |
| Sep 1, 2026Form 4 | Guyer WilliamChief Development OfficerAward · $19K · 328 sh |
| Sep 1, 2026Form 4 | Maduck SeanSee RemarksAward · $17K · 300 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Vieira Roberto WandenkolkPresident, OncologyAward · $16K · 276 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Mokari AtabakChief Financial OfficerAward · $16K · 276 sh |
| Sep 1, 2026Form 4 | Lyon Joseph DouglasSee RemarksAward · $15K · 260 sh |
| Sep 1, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 25,000 sh · 10b5-1 |
| Aug 26, 2026Form 4 | Park KimberlyDirectorTax withholding · $405K · 3,315 sh |
| Aug 26, 2026Form 4 | Park KimberlyDirectorExercise or conversion · $405K · 30,000 sh |
| Aug 26, 2026Form 4 | Park KimberlyDirectorExercise or conversion · Stock Option (right to buy) · $0 · 30,000 sh |
| Aug 25, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $351K · 30,955 sh · 10b5-1 |
| Aug 25, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 30,955 sh · 10b5-1 |
| Aug 17, 2026Form 4 | Robb Gary CharlesChief Business OfficerGift · $0 · 125 sh |
| Aug 14, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $30K · 3,664 sh · 10b5-1 |
| Aug 14, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 3,664 sh · 10b5-1 |
| Aug 12, 2026Form 4 | Robb Gary CharlesChief Business OfficerGift · $0 · 17,530 sh |
| Aug 10, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $353K · 16,300 sh · 10b5-1 |
| Aug 10, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $8,526 · 1,031 sh · 10b5-1 |
| Aug 10, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 16,300 sh · 10b5-1 |
| Aug 10, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 1,031 sh · 10b5-1 |
| Aug 4, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $80K · 3,700 sh · 10b5-1 |
| Aug 4, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 3,700 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $168K · 20,305 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 20,305 sh · 10b5-1 |
| Jul 30, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · $1.8M · 80,000 sh · 10b5-1 |
| Jul 30, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 80,000 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · $862K · 40,000 sh · 10b5-1 |
| Jul 15, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 40,000 sh · 10b5-1 |
| Jul 7, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1 |
| Jul 7, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $207K · 25,000 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 25,000 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · $770K · 40,000 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 40,000 sh · 10b5-1 |
| Jun 2, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1 |
| Jun 2, 2026Form 4 | Maduck SeanSee RemarksTax withholding · $32K · 452 sh · 10b5-1 |
| Jun 2, 2026Form 4 | Mokari AtabakChief Financial OfficerTax withholding · $28K · 395 sh · 10b5-1 |
| Jun 2, 2026Form 4 | Robb Gary CharlesChief Business OfficerTax withholding · $25K · 358 sh |
| Jun 2, 2026Form 4 | Lyon Joseph DouglasSee RemarksTax withholding · $19K · 269 sh |
| Jun 2, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · $770K · 40,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $207K · 25,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Guyer WilliamChief Development OfficerAward · $62K · 1,754 sh |
| Jun 1, 2026Form 4 | Robb Gary CharlesChief Business OfficerAward · $55K · 1,552 sh |
| Jun 1, 2026Form 4 | Mokari AtabakChief Financial OfficerAward · $45K · 1,268 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Maduck SeanSee RemarksAward · $43K · 1,230 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Lyon Joseph DouglasSee RemarksAward · $38K · 1,074 sh |
| Jun 1, 2026Form 4 | Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 40,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 25,000 sh · 10b5-1 |
| May 29, 2026Form 4 | BELANOFF JOSEPH KChief Executive Officer · DirectorGift · $0 · 600,000 sh · 10b5-1 |
| May 27, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · $620K · 75,000 sh · 10b5-1 |
| May 27, 2026Form 4 | WILSON JAMES NDirectorGift · $0 · 910,078 sh |
| May 27, 2026Form 4 | Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 75,000 sh · 10b5-1 |
| May 27, 2026Form 4 | Robb Gary CharlesChief Business OfficerGift · $0 · 600 sh |
| May 21, 2026Form 4 | Park KimberlyDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh |
| May 21, 2026Form 4 | MAHONEY DAVID LDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh |
| May 21, 2026Form 4 | Murray Joshua M.DirectorAward · Stock Option (right to buy) · $0 · 12,500 sh |
| May 21, 2026Form 4 | Swisher Daniel N JRDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh |
| May 21, 2026Form 4 | WILSON JAMES NDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh |
| May 21, 2026Form 4 | Alton Gregg HDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh |
| May 21, 2026Form 4 | BAKER G LEONARD JRDirectorAward · Stock Option (Right To Buy) · $0 · 12,500 sh |
| May 13, 2026Form 4 | Robb Gary CharlesChief Business OfficerGift · $0 · 7,300 sh |
| May 5, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1 |
| May 5, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1 |
| Apr 22, 2026Form 4 | WILSON JAMES NDirectorGift · $0 · 2,000 sh |
| Apr 7, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1 |
| Apr 7, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1 |
| Apr 6, 2026Form 4 | WILSON JAMES NDirectorGift · $0 · 5,000 sh |
| Mar 20, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $255K · 11,767 sh · 10b5-1 |
| Mar 20, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 11,767 sh · 10b5-1 |
| Mar 20, 2026Form 4 | WILSON JAMES NDirectorGift · $0 · 4,000 sh |
| Mar 13, 2026Form 4 | MAHONEY DAVID LDirectorTax withholding · $176K · 5,469 sh |
| Mar 13, 2026Form 4 | MAHONEY DAVID LDirectorExercise or conversion · $176K · 30,000 sh |
| Mar 13, 2026Form 4 | MAHONEY DAVID LDirectorExercise or conversion · Stock Option (right to buy) · $0 · 30,000 sh |
| Mar 13, 2026Form 4 | WILSON JAMES NDirectorGift · $0 · 28,000 sh |
| Mar 13, 2026Form 4 | MAHONEY DAVID LDirectorGift · $0 · 24,531 sh |
| Mar 13, 2026Form 4 | MAHONEY DAVID LDirectorOther · $0 · 24,531 sh |
| Mar 4, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $178K · 8,233 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 8,233 sh · 10b5-1 |
| Mar 3, 2026Form 4 | Robb Gary CharlesChief Business OfficerTax withholding · $4,352 · 121 sh |
| Mar 3, 2026Form 4 | Maduck SeanSee RemarksTax withholding · $3,957 · 110 sh |
| Mar 3, 2026Form 4 | Mokari AtabakChief Financial OfficerTax withholding · $3,453 · 96 sh |
| Mar 3, 2026Form 4 | Lyon Joseph DouglasSee RemarksTax withholding · $3,201 · 89 sh |
| Mar 2, 2026Form 4 | Robb Gary CharlesChief Business OfficerAward · $18K · 998 sh |
| Mar 2, 2026Form 4 | Guyer WilliamChief Development OfficerAward · $18K · 996 sh |
| Mar 2, 2026Form 4 | Maduck SeanSee RemarksAward · $16K · 908 sh |
| Mar 2, 2026Form 4 | Lyon Joseph DouglasSee RemarksAward · $14K · 796 sh |
| Mar 2, 2026Form 4 | Mokari AtabakChief Financial OfficerAward · $14K · 794 sh |
| Feb 27, 2026Form 4 | BELANOFF JOSEPH KChief Executive Officer · DirectorAward · Stock Option (right to buy) · $0 · 460,000 sh |
| Feb 27, 2026Form 4 | Guyer WilliamChief Development OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh |
| Feb 27, 2026Form 4 | Robb Gary CharlesChief Business OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh |
| Feb 27, 2026Form 4 | Hunt HazelChief Scientific OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh |
| Feb 27, 2026Form 4 | Maduck SeanSee RemarksAward · Stock Option (right to buy) · $0 · 140,000 sh |
| Feb 27, 2026Form 4 | Mokari AtabakChief Financial OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh |
| Feb 27, 2026Form 4 | Lyon Joseph DouglasSee RemarksAward · Stock Option (right to buy) · $0 · 140,000 sh |
| Feb 24, 2026Form 4 | WILSON JAMES NDirectorTax withholding · $388K · 10,636 sh |
| Feb 24, 2026Form 4 | WILSON JAMES NDirectorExercise or conversion · $388K · 100,000 sh |
| Feb 24, 2026Form 4 | WILSON JAMES NDirectorExercise or conversion · Stock option (right to buy) · $0 · 100,000 sh |
| Feb 24, 2026Form 4 | WILSON JAMES NDirectorGift · $0 · 89,364 sh |
| Feb 24, 2026Form 4 | WILSON JAMES NDirectorOther · $0 · 89,364 sh |
| Feb 9, 2026Form 4 | Hunt HazelChief Scientific OfficerTax withholding · $3.2M · 77,968 sh |
| Feb 9, 2026Form 4 | Hunt HazelChief Scientific OfficerExercise or conversion · $582K · 150,000 sh |
| Feb 9, 2026Form 4 | Hunt HazelChief Scientific OfficerExercise or conversion · Stock Option (right to buy) · $0 · 150,000 sh |
| Feb 3, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1 |
| Feb 3, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock option (right to buy) · $0 · 20,000 sh · 10b5-1 |
| Jan 27, 2026Form 4 | BAKER G LEONARD JRDirectorExercise or conversion · $1.6M · 140,000 sh |
| Jan 27, 2026Form 4 | BAKER G LEONARD JRDirectorExercise or conversion · Stock Option (Right To Buy) · $0 · 140,000 sh |
| Jan 8, 2026Form 4 | Maduck SeanSee RemarksGift · $0 · 54,570 sh |
| Jan 8, 2026Form 4 | Maduck SeanSee RemarksOther · $0 · 54,570 sh |
| Jan 6, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1 |
| Jan 6, 2026Form 4 | Guyer WilliamChief Development OfficerExercise or conversion · Stock option (right to buy) · $0 · 20,000 sh · 10b5-1 |
| Jan 1, 2026Form 4 | BAKER G LEONARD JRDirectorGift · $0 · 0 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).
2026 · 14 filings
| Filed | What it is |
|---|---|
| Sep 23, 20268-K | Directors or officers; compensation; Regulation FD disclosure |
| Jul 29, 202610-Q | Quarterly report, Q2 2026 — revenue $256.1M (+32% y/y), net income $43.0M, EPS $0.36 |
| Jul 29, 20268-K | Earnings release — EPS $0.36 vs −$0.04 est. (+1000.0%); revenue $256.1M (+32% y/y) 27.3% |
| Jun 17, 20268-K | Other events |
| Jun 3, 20268-K | Other events |
| May 28, 20268-K | Directors or officers; compensation; Shareholder vote results |
| Apr 30, 202610-Q | Quarterly report, Q1 2026 — revenue $164.9M (+5% y/y), net income −$31.8M, EPS −$0.30 |
| Apr 30, 20268-K | Earnings release — EPS −$0.30 vs −$0.30 est. (+0.0%); revenue $164.9M (+5% y/y) 10.5% |
| Apr 17, 2026DEF 14A | Proxy statement |
| Mar 25, 20268-K | Other events |
| Feb 24, 202610-K | Annual report, FY2025 — revenue $761.4M (+13% y/y), net income $99.7M, EPS $0.82 |
| Feb 24, 20268-K | Earnings release — EPS $0.20 vs $0.27 est. (−25.9%); revenue $202.1M (+11% y/y) 0.7% |
| Feb 19, 20268-K | Other events |
| Jan 22, 20268-K | Other events |
2025 · 17 filings
| Filed | What it is |
|---|---|
| Dec 31, 20258-K | Other events |
| Nov 4, 202510-Q | Quarterly report, Q3 2025 — revenue $207.6M (+14% y/y), net income $19.7M, EPS $0.16 |
| Nov 4, 20258-K | Earnings release — EPS $0.16 vs $0.18 est. (−11.1%); revenue $207.6M (+14% y/y) 7.8% |
| Oct 14, 20258-K | Termination of a material agreement |
| Oct 6, 20258-K | Directors or officers; compensation |
| Sep 10, 20258-K | Other events |
| Jul 31, 202510-Q | Quarterly report, Q2 2025 — revenue $194.4M (+19% y/y), net income $35.1M, EPS $0.29 |
| Jul 31, 20258-K | Results of operations; Regulation FD disclosure |
| Jul 14, 20258-K | Other events |
| Jun 16, 20258-K | Shareholder vote results |
| May 5, 202510-Q | Quarterly report, Q1 2025 — revenue $157.2M (+7% y/y), net income $20.5M, EPS $0.17 |
| May 5, 20258-K | Results of operations; Regulation FD disclosure |
| Apr 25, 2025DEF 14A | Proxy statement |
| Mar 31, 20258-K | Other events |
| Mar 3, 20258-K | Other events |
| Feb 26, 202510-K | Annual report, FY2024 — revenue $675.0M (+40% y/y), net income $141.2M, EPS $1.23 |
| Feb 26, 20258-K | Results of operations; Regulation FD disclosure |
2024 · 16 filings
| Filed | What it is |
|---|---|
| Dec 30, 20248-K | Other events |
| Oct 30, 202410-Q | Quarterly report, Q3 2024 — revenue $182.5M (+48% y/y), net income $47.2M, EPS $0.41 |
| Oct 30, 20248-K | Results of operations; Regulation FD disclosure |
| Jul 29, 202410-Q | Quarterly report, Q2 2024 — revenue $163.8M (+39% y/y), net income $35.5M, EPS $0.32 |
| Jul 29, 20248-K | Results of operations; Regulation FD disclosure |
| May 23, 20248-K | Directors or officers; compensation; Shareholder vote results |
| May 1, 202410-Q | Quarterly report, Q1 2024 — revenue $146.8M (+39% y/y), net income $27.8M, EPS $0.25 |
| May 1, 20248-K | Results of operations; Regulation FD disclosure |
| Apr 18, 2024DEFA14A | Additional proxy materials |
| Apr 17, 2024ARS | Annual report to shareholders |
| Apr 17, 20248-K | Material definitive agreement; New financial obligation |
| Apr 10, 2024DEF 14A | Proxy statement |
| Feb 15, 202410-K | Annual report, FY2023 — revenue $482.4M (+20% y/y), net income $106.1M, EPS $0.94 |
| Feb 15, 20248-K | Results of operations; Regulation FD disclosure |
| Jan 8, 20248-K | Results of operations; Other events |
| Jan 2, 20248-K | Other events |
2023 · 15 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
| Filed | What it is |
|---|---|
| Nov 1, 202310-Q | Quarterly report, Q3 2023 — revenue $123.6M (+22% y/y), net income $31.4M, EPS $0.28 |
| Aug 2, 202310-Q | Quarterly report, Q2 2023 — revenue $117.7M (+14% y/y), net income $27.5M, EPS $0.25 |
| May 8, 2023DEFA14A | Additional proxy materials |
| May 3, 202310-Q | Quarterly report, Q1 2023 — revenue $105.7M (+13% y/y), net income $15.9M, EPS $0.14 |
| Apr 14, 2023ARS | Annual report to shareholders |
| Apr 14, 2023DEF 14A | Proxy statement |
| Apr 4, 2023PRE 14A | Preliminary proxy statement |
| Feb 28, 202310-K | Annual report, FY2022 — revenue $401.9M (+10% y/y), net income $101.4M, EPS $0.87 |
7 current reports (8-K) not listed; the year is on EDGAR.
2022 · 12 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 3, 202210-Q | Quarterly report, Q3 2022 — revenue $101.7M (+6% y/y), net income $34.6M, EPS $0.30 |
| Aug 4, 202210-Q | Quarterly report, Q2 2022 — revenue $103.4M (+13% y/y), net income $27.4M, EPS $0.24 |
| May 5, 202210-Q | Quarterly report, Q1 2022 — revenue $93.7M (+18% y/y), net income $22.8M, EPS $0.20 |
| Apr 25, 2022DEF 14A | Proxy statement |
| Feb 15, 202210-K | Annual report, FY2021 — revenue $366.0M (+3% y/y), net income $112.5M, EPS $0.89 |
7 current reports (8-K) not listed; the year is on EDGAR.
2021 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 15, 202110-K/A | Annual report, amended |
| Nov 3, 202110-Q | Quarterly report, Q3 2021 — revenue $96.1M (+11% y/y), net income $30.5M, EPS $0.24 |
| Jul 29, 202110-Q | Quarterly report, Q2 2021 — revenue $91.6M (+3% y/y), net income $26.5M, EPS $0.21 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $79.4M (−15% y/y), net income $23.5M, EPS $0.18 |
| Apr 22, 2021DEF 14A | Proxy statement |
| Feb 23, 202110-K | Annual report, FY2020 — revenue $353.9M (+15% y/y), net income $106.0M, EPS $0.85 |
12 current reports (8-K) not listed; the year is on EDGAR.
2020 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 3, 202010-Q | Quarterly report, Q3 2020 — revenue $86.3M (+6% y/y), net income $21.6M, EPS $0.17 |
| Aug 4, 202010-Q | Quarterly report, Q2 2020 — revenue $88.6M (+23% y/y), net income $28.3M, EPS $0.23 |
| May 4, 202010-Q | Quarterly report, Q1 2020 — revenue $93.2M (+44% y/y), net income $30.1M, EPS $0.25 |
| Apr 27, 2020DEF 14A | Proxy statement |
| Feb 24, 202010-K | Annual report, FY2019 — revenue $306.5M (+22% y/y), net income $94.2M, EPS $0.77 |
10 current reports (8-K) not listed; the year is on EDGAR.
2019 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 7, 201910-Q | Quarterly report, Q3 2019 — revenue $81.5M (+26% y/y), net income $26.3M, EPS $0.22 |
| Aug 1, 201910-Q | Quarterly report, Q2 2019 — revenue $72.3M (+16% y/y), net income $20.2M, EPS $0.17 |
| May 9, 201910-Q | Quarterly report, Q1 2019 — revenue $64.8M (+12% y/y), net income $18.3M, EPS $0.15 |
| Apr 24, 2019DEF 14A | Proxy statement |
| Feb 26, 201910-K | Annual report, FY2018 — revenue $251.2M (+58% y/y), net income $75.4M, EPS $0.60 |
9 current reports (8-K) not listed; the year is on EDGAR.
2018 · 16 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 2, 201810-Q | Quarterly report, Q3 2018 — revenue $64.4M (+51% y/y), net income $17.7M, EPS $0.14 |
| Aug 9, 201810-Q | Quarterly report, Q2 2018 — revenue $62.3M (+75% y/y), net income $18.2M, EPS $0.14 |
| May 9, 201810-Q | Quarterly report, Q1 2018 — revenue $57.7M (+109% y/y), net income $17.5M, EPS $0.14 |
| Apr 24, 2018DEF 14A | Proxy statement |
| Feb 28, 201810-K | Annual report, FY2017 — revenue $159.2M (+96% y/y), net income $129.1M, EPS $1.04 |
11 current reports (8-K) not listed; the year is on EDGAR.
2017 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 3, 201710-Q | Quarterly report, Q3 2017 — revenue $42.8M, net income $13.8M, EPS $0.11 |
| Aug 2, 201710-Q | Quarterly report, Q2 2017 — revenue $35.6M, net income $12.6M, EPS $0.10 |
| May 2, 201710-Q | Quarterly report, Q1 2017 — revenue $27.6M, net income $4.4M, EPS $0.04 |
| Apr 21, 2017DEF 14A | Proxy statement |
| Mar 6, 201710-K | Annual report, FY2016 — revenue $81.3M, net income $8.1M, EPS $0.07 |
9 current reports (8-K) not listed; the year is on EDGAR.
2016 · 12 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2015 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2014 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2013 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2012 · 18 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2011 · 24 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2010 · 24 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2008 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2007 · 24 filings — 16 × 8-K, 3 × 10-Q, 2 × DEF 14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2006 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2004 · 10 filings — 7 × 8-K, 3 × 10-Q
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 113 filings — 81 × 4, 26 × 144, 4 × SCHEDULE 13G/A and 2 other forms
| Filed | What it is |
|---|---|
| Oct 1, 2026144 | Notice of proposed sale (Form 144) |
| Sep 28, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 16, 20264 | Insider transaction (Form 4) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 14, 2026144 | Notice of proposed sale (Form 144) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 20263 | Initial insider holdings (Form 3) |
| Sep 2, 2026144 | Notice of proposed sale (Form 144) |
| Aug 28, 20264 | Insider transaction (Form 4) |
| Aug 27, 20264 | Insider transaction (Form 4) |
| Aug 26, 2026144 | Notice of proposed sale (Form 144) |
| Aug 25, 2026144 | Notice of proposed sale (Form 144) |
| Aug 20, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 2026144 | Notice of proposed sale (Form 144) |
The newest 25 of 113 shown; the full year is on EDGAR.
2025 · 170 filings — 98 × 4, 63 × 144, 4 × SCHEDULE 13G/A and 4 other forms
| Filed | What it is |
|---|---|
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 11, 2025UPLOAD | Letter from the SEC staff |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254 | Insider transaction (Form 4) |
| Dec 3, 20254/A | Insider transaction (Form 4), amended |
| Dec 2, 2025144 | Notice of proposed sale (Form 144) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Dec 1, 2025144 | Notice of proposed sale (Form 144) |
| Nov 26, 20254 | Insider transaction (Form 4) |
| Nov 25, 2025144 | Notice of proposed sale (Form 144) |
| Nov 7, 20254 | Insider transaction (Form 4) |
| Nov 5, 20254 | Insider transaction (Form 4) |
| Nov 5, 20254 | Insider transaction (Form 4) |
| Nov 5, 20254 | Insider transaction (Form 4) |
| Nov 5, 2025144 | Notice of proposed sale (Form 144) |
| Nov 3, 2025144 | Notice of proposed sale (Form 144) |
| Nov 3, 2025144 | Notice of proposed sale (Form 144) |
| Nov 3, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 170 shown; the full year is on EDGAR.
2024 · 126 filings — 75 × 4, 31 × 144, 11 × S-8 POS and 3 other forms
| Filed | What it is |
|---|---|
| Dec 31, 20244 | Insider transaction (Form 4) |
| Dec 12, 20244 | Insider transaction (Form 4) |
| Dec 10, 2024144 | Notice of proposed sale (Form 144) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Dec 4, 20244 | Insider transaction (Form 4) |
| Nov 26, 20244 | Insider transaction (Form 4) |
| Nov 26, 20244 | Insider transaction (Form 4) |
| Nov 22, 2024144 | Notice of proposed sale (Form 144) |
| Nov 22, 2024144 | Notice of proposed sale (Form 144) |
| Nov 13, 20244 | Insider transaction (Form 4) |
| Nov 12, 2024144 | Notice of proposed sale (Form 144) |
| Nov 5, 20244 | Insider transaction (Form 4) |
| Nov 1, 2024144 | Notice of proposed sale (Form 144) |
| Oct 3, 20244 | Insider transaction (Form 4) |
| Oct 1, 20244 | Insider transaction (Form 4) |
| Oct 1, 2024144 | Notice of proposed sale (Form 144) |
| Oct 1, 2024144 | Notice of proposed sale (Form 144) |
| Sep 19, 20244 | Insider transaction (Form 4) |
| Sep 5, 20244 | Insider transaction (Form 4) |
| Sep 5, 20244 | Insider transaction (Form 4) |
| Sep 5, 20244 | Insider transaction (Form 4) |
| Sep 5, 20244 | Insider transaction (Form 4) |
The newest 25 of 126 shown; the full year is on EDGAR.
2023 · 111 filings — 69 × 4, 23 × 144, 6 × SC 13G/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2022 · 51 filings — 40 × 4, 6 × SC 13G/A, 2 × 5 and 3 other forms
Counted, not listed; the year is on EDGAR.
2021 · 61 filings — 42 × 4, 4 × SC 13G/A, 4 × SC TO-I/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2020 · 50 filings — 31 × 4, 7 × SC 13G/A, 4 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2019 · 30 filings — 19 × 4, 5 × SC 13G/A, 2 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2018 · 43 filings — 33 × 4, 4 × SC 13G/A, 2 × SC 13G and 4 other forms
Counted, not listed; the year is on EDGAR.
2017 · 45 filings — 22 × 4, 4 × 5, 3 × CORRESP and 10 other forms
Counted, not listed; the year is on EDGAR.
2016 · 34 filings — 27 × 4, 3 × SC 13G/A, 1 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 61 filings — 47 × 4, 4 × SC 13G/A, 2 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2014 · 26 filings — 16 × 4, 4 × SC 13G/A, 2 × CT ORDER and 4 other forms
Counted, not listed; the year is on EDGAR.
2013 · 29 filings — 15 × 4, 5 × 5, 4 × SC 13G/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2012 · 64 filings — 36 × 4, 5 × SC 13G/A, 4 × CT ORDER and 12 other forms
Counted, not listed; the year is on EDGAR.
2011 · 67 filings — 49 × 4, 6 × SC 13G/A, 2 × 5 and 9 other forms
Counted, not listed; the year is on EDGAR.
2010 · 68 filings — 28 × 4, 6 × EFFECT, 5 × SC 13G/A and 13 other forms
Counted, not listed; the year is on EDGAR.
2009 · 95 filings — 56 × 4, 18 × 424B3, 4 × 4/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2008 · 107 filings — 59 × 4, 6 × CORRESP, 5 × 3 and 14 other forms
Counted, not listed; the year is on EDGAR.
2007 · 106 filings — 69 × 4, 9 × SC 13G/A, 6 × 424B3 and 10 other forms
Counted, not listed; the year is on EDGAR.
2006 · 78 filings — 71 × 4, 3 × SC 13G/A, 2 × SC 13G and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 80 filings — 70 × 4, 7 × SC 13G, 2 × 3 and 1 other form
Counted, not listed; the year is on EDGAR.
2004 · 53 filings — 24 × 4, 20 × 3, 3 × S-1/A and 6 other forms
Counted, not listed; the year is on EDGAR.
2003 · 1 filing — 1 × REGDEX/A
Counted, not listed; the year is on EDGAR.
2002 · 2 filings — 1 × RW, 1 × S-1/A
Counted, not listed; the year is on EDGAR.
2001 · 1 filing — 1 × S-1
Counted, not listed; the year is on EDGAR.
About this data
Corcept Therapeutics Incorporated (CORT) has 2,038 filings on EDGAR going back to 2001: 24 annual reports, 69 quarterly reports and 243 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Sep 23, 2026, covered directors or officers; compensation; regulation fd disclosure. Over the last 13 months insiders sold $81.5M in 38 sales and bought $3.3M in 1 purchase; 125 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Corcept Therapeutics Incorporated, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read CORT's latest 10-K?
- CORT's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did CORT last file an 8-K?
- On Sep 23, 2026: directors or officers; compensation; regulation fd disclosure. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 29, 2026.
- Are CORT insiders buying or selling?
- Over the last 13 months insiders sold $81.5M in 38 sales and bought $3.3M in 1 purchase; 125 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Vieira Roberto Wandenkolk (President, Oncology) sold 296 shares on Sep 16, 2026 for $30K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has CORT made?
- 2,038 filings are on EDGAR under the registrant records that have been Corcept Therapeutics Incorporated, going back to 2001; 1,331 of them are insider ownership forms (Forms 3, 4, 5 and 144).